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1 | INTRODUCTION
Modern Americans cannot live a day without being inun-
dated by genetic and genomic information. From television
commercials promoting DNA-based testing for colon can-
cer and ancestry panels to Internet ads for DNA testing for
drug interactions and to find the perfect life partner, DNA-
based testing is expected to cure, entertain, and even find
all of us happiness. As the first Genetics in the USA article
showed the long history of genetics in creating a culture of
diagnosis and care for patients, this article will continue the
story and share the advances in the last century and how
modern medicine, everyday life, and our every day beliefs
have been affected by genetics. Or in short, how DNA has
“helixed” itself into the culture of the United States.
2 | THE HISTORY OF DNA
Europe was the home of early DNA understanding. In the
1860s, the Austrian Gregor Mendel described his experi-
ments in peas showing inheritance and became known as
the father of genetics. In the 1950s the structure of DNA
was elucidated with the work of Rosalind Franklin, Mau-
rice Wilkins, Francis Crick, and the American James Wat-
son while in Europe. In the 1970s a group in Europe
developed Sanger sequencing (Sanger, Nicklen, & Coulson,
1977), whereas the Massachusetts based group of Maxam
and Gilbert developed a chemical sequencing mechanism
(Maxam & Gilbert, 1977). While Sanger sequencing went
on to become the more cost-effective mechanism, this
showed the cooperation between scientists in Europe and
the United States to move forward the field of genetics. In
1983 Kary Mullis described the polymerase chain reaction,
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or PCR, which allowed for DNA to be efficiently copied in
the laboratory (Mullis et al., 1986). His work to identify
thermostable polymerases earned him the Nobel Prize in
Chemistry in 1993. It was the combination of Sanger
sequencing, computational abilities made possible by super
computers, and PCR that allowed for the launch of the
Human Genome Project, an international scientific project
to determine the sequence of base pairs that makes up the
human genome with the goal of creating a physical and
functional map. This project was launched in 1990 and
funded by the National Institutes of Health and the Depart-
ment of Energy. The project included groups from across
the United States and the world. Its completion in April
2003 was 2 years ahead of schedule. By then, over 92% of
the human genome had been sequenced, which included
over 99% of euchoromatic DNA, with greater than 99.99%
accuracy (Schmutz et al., 2004). The key findings of this
multiyear, multinational project were the following:
1. 22,300 protein-coding genes in humans, similar to other
mammals (Pertea & Salzberg, 2010);
2. Larger numbers of segmental duplications than had been
previous expected (International Human Genome
Sequencing Consortium, 2004);
3. Less than 7% of the protein family groups were verte-
brate-specific.
Since the completion of the human genome project, the
project has already led to the discovery of more than 1,800
disease genes, 350 biotechnology-based products, and
2,000 genetic tests for human conditions (NIH Fact Sheets
– Human Genome Project). Now in the post-Human Gen-
ome Project era, the work has shifted to combining the dis-
orders described by earlier clinicians with the DNA
information provided. Thus, the post-Human Genome Pro-
ject field of medical genetics is a bold new world with
more complexities than we ever imagined and more hope
for future treatments and improved outcomes than we could
have dreamed.
3 | PRENATAL DIAGNOSIS AND
SCREENING
With the delineation of genetic syndromes and the identifi-
cation of proteins involved, the use of preconception
screening became common. First widely used in the Ashke-
nazi Jewish population for Tay–Sachs disease in the 1970s,
by measuring enzyme activity in adults, carriers of the dis-
order could be detected and reproductive risk addressed in
this autosomal recessive disorder. With the expansion of
genetic evaluation and sequence changes that are com-
monly found in rare diseases, screening panels for carrier
states became available. Both the American College of
Medical Genetics and Genomics (ACMGG) and the Ameri-
can College of Obstetrics and Gynecology (ACOG) have
recommended carrier screening in populations at high risk
for rare disorders (i.e., Ashkenazi Jews, or in all popula-
tions for cystic fibrosis) (Gross, Pletcher, & Monaghan,
2008). From single disorder panels for common variants in
the Mennonite, Amish, and Jewish populations to identifi-
cation of the triplet repeat number that is responsible for
Fragile X to a pan-ethnic screen that covers thousands of
the most common genetic changes leading to rare disor-
ders, the use of DNA to identify carriers of rare autosomal
recessive, X-linked, and autosomal dominant disorders has
become common place in Western medicine. While the
ACMGG and the ACOG have yet to endorse specific
broadened panels, they have endorsed ensuring that labora-
tories performing testing use best practices (Grody et al.,
2013). This publication was to ensure accuracy for the tests
that are in use and leading to decision-making either before
or during a possibly affected pregnancy.
The FDA has become involved in the field of carrier
testing. In November 2013, they warned a direct-to-consu-
mer company that their product required FDA approval
due to it being a new “medical device” (Warning Letters –
23andMe, Inc. 11/22/13). Over the past several years, the
field has evolved to include ancestry testing and commer-
cials asking the consumer to “ask your doctor” for genetic
testing. As of the time of writing this article, direct-to-con-
sumer testing for ancestry determination is commercially
available. However, testing for medically actionable results
remain under the regulation of physician orders.
With the ability to leverage DNA information for health
advances, the role of this information in prenatal screening
and testing has been an ongoing ethical and medical
debate. For more than 30 years, prenatal genetics focused
on the creation of screening programs that would allow for
noninvasive mechanisms to determine risk for fetal disor-
ders. The combination of maternal serum and ultrasound
evaluation were the basis of these screens. The emphasis
was on Down syndrome, based on the frequency of this
disorder. In addition, maternal serum screening was found
to be useful for the detection of Down syndrome, trisomy
18, trisomy 13, and neural tube defects. While these
screening tests were helpful, the use of chorionic villi sam-
pling—removal of a small piece of placenta—or amniocen-
tesis—removal of a small amount of amniotic fluid—was
needed to perform a karyotype, the gold standard test for
aneuploidy disorders. For neural tube defects, the second
line testing was ultrasound evaluation, as elegantly
reviewed by Van den Veyver (2016). With the launch of
microarray analysis, a technique that evaluates for submi-
croscopic deletions and duplications, the use of invasive
testing for diagnosis began. In 2013, the ACOG released a
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recommendation that “in patients with a fetus with one or
more major structural abnormalities identified on ultrasono-
graphic examination and who are undergoing invasive pre-
natal diagnosis, chromosomal microarray analysis is
recommended” (American College of Obstetricians and
Gynecologists Committee on Genetics, 2013).
The field of prenatal genetic testing had historical accel-
eration when Lo et al. discovered that fetal DNA could be
amplified form maternal plasma (1997). This seminal work
launched into clinical significance in 2008 when two
groups showed that this fetal DNA could be used to deter-
mine fetal aneuploidy status (Chiu et al., 2008; Fan, Blu-
menfeld, Chitkara, Hudgins, & Quake, 2008). And that
was the start of a whole new realm of screening. With sen-
sitivities greater than 98% and specificities in the 90%s, the
ACOG now recommends cell-free fetal DNA evaluation
for all women of advanced maternal age. In many clinical
practices, this is offered to all patients due to the noninva-
sive nature of the test. And the ACMGG updated their
practice guidelines to recommend “informing all pregnant
women that NIPS (noninvasive prenatal screening) is the
most sensitive screening option for traditionally screened
aneuploidies” (Gregg et al., 2016). In this same publica-
tion, they did NOT recommend screening for smaller dele-
tion syndromes due to the sensitivity and specificity of
testing (i.e. 22q11 deletion syndrome).
4 | THE HISTORY OF METABOLIC
GENETICS AND NEWBORN
SCREENING
In the pregenomics era, biochemical genetics was not depen-
dent on clinical findings alone, but was based on biochemi-
cal markers of disease. As DNA-based genetics has evolved
in the last half-century, so too has the world of biochemical
genetics. The earliest identified metabolic disorder, alkap-
tonuria, was described by British physician Archibald Gar-
rod (Piro, Tagarelli, Lagonia, Quattrone, & Tagarelli, 2010).
As certain biochemical markers were identified, the physi-
cians worked to find ways to decrease these levels, in an
attempt to create treatment plans. One of the illustrious
examples is in the work of Norwegian-born Asbjørn Følling
in the 1930s. He carefully evaluated and identified accumu-
lation of phenylpyruvic acid in the urine of children affected
with a disease that thus came to be called phenylketonuria
(PKU). In the 1950s, the German physician Horst Bickel
identified a low phenylalanine diet as prevention for the
neurodisability seen in untreated PKU. This began a new
era, where early diagnosis led to a treatment that could pre-
vent or slow down disease progression. When American-
born Robert Guthrie had a niece diagnosed with PKU, he
used his skills in bacterial inhibition assays to identify a
way to identify patients presymptomatically. He developed
an assay that used whole blood that was spotted onto a filter
paper card. The Guthrie test and Guthrie card became the
first steps in a newborn screening system. In this system,
Bacillus subtilis was plated on an agar plate with a pheny-
lalanine antagonist. Samples with very high amounts of
phenylalanine (i.e., babies affected with PKU) could over-
come this inhibition and had rapid growth of the bacteria
(Gonzalez & Willis, 2009). By identifying babies with ele-
vated phenylalanine levels BEFORE neurological symptoms
occurred, treatment could be begun to prevent complica-
tions. This was the launch of the newborn screening pro-
gram in the United States. Massachusetts was the first state
to perform universal, mandatory screening for PKU in 1963.
Gradually, the other states adopted PKU screening. Since
each state chose the screening to be performed, by the mid
2000s, there was significant disparity between states. The
Maternal and Child Health Bureau of the Health Resources
and Services Administration (HRSA) and the ACMGG
began a joint project to create standardization for states. The
2007 federal Newborn Screening Saves Lives Act of 2007
had provisions to establish seven HRSA-supported regional
centers and support for newborn screening, including the
creation of the Recommended Uniform Screening
Panel (RUSP). The RUSP is a list of recommended screens
from the Secretary of Health and Human Services. The com-
mittee that makes these recommendations uses the criteria
for disorders that have improved outcomes if identified and
treated early (reviewed by Sue Berry, 2015).
Initially, newborn screening was a “one test for one dis-
order” system, such as that developed for PKU. However,
with advances in metabolic medicine, the process of using
dried blood spots for evaluation by tandem mass spectrom-
etry allowed for one blood spot to be used to assess for
dozens of molecules and conditions. Similarly, using hemo-
globin electrophoresis, one sample was able to assess for
multiple hemoglobiniopathies simultaneously. This work to
increase the effectiveness of the test and decrease the turn-
around time on samples has led to a robust and ever-
improving system designed to keep babies safe.
The Centers for Disease Control has included newborn
screening on the top ten accomplishments of public health.
This program screens more than 90% of babies born in the
United States for dozens of disorders that can be treated
early to prevent or minimize disease progression. As one
of the proudest accomplishments of metabolic genetics, the
field of newborn screening is ever advancing. In the last
years, the RUSP has continued to recommend screening
new disorders, now including some lysosomal storage dis-
orders and peroxisomal disorders.
With the advancements in metabolic diagnosis, the role
of improving management has also evolved. Enzyme
replacement therapies for lysosomal storage disorders,
REGIER ET AL. | 623
ammonia scavenger agents for urea cycle disorders, and
small molecule cofactors have revolutionized the world of
metabolic medicine in the last decades. These treatments
along with improved early death prevention have led to a
new generation of patients with chronic disease. For exam-
ple, women with PKU are at a high risk of having babies
with major malformations if their phenylalanine levels are
not well controlled. While a hundred years ago, this would
have never been a public health concern, now the recom-
mendation of “low phenylalanine diet for life” is partly
based on these findings (Regier & Greene, 1993).
As the population of children with treated metabolic dis-
orders age, the field continues to discover how the newly
treated disorders have their own unique natural histories.
The world of treated disorders is only beginning and will
certainly be the story of the 21st century in biochemical
genetics.
The worlds of biochemical and medical genetics have
merged in the realm of prenatal diagnosis. While the gold
standard of biochemical genetics is chemical marker testing,
identifying patients based on genetic changes has allowed
for prenatal diagnosis, identification of groups of patients
that will be most amenable to types of treatments, and
recurrence risk. Prenatal diagnosis can be performed at vari-
ous stages. A child with a metabolic disorder can have
genetic testing to identify the gene changes leading to this
diagnosis. While not always informative, this testing is con-
sidered standard of care for many diagnoses. This testing
can be used for selection of embryos for implantation in
in vitro fertilization therapy, for identification of affected
fetuses using CVS or amniocentesis, or for early postnatal
testing using cord blood or neonatal specimens. Second,
genetic sequencing can be used to identify the most optimal
treatment plans. For example, the biopku.org database con-
tains hundreds of genetic changes associated with PKU. In
each case, they have data showing the response rate to a
cofactor treatment that is effective in some patients with
PKU (sapropterin dihydrochloride, an isomer of tetrahydro-
biopterin). The current guidelines suggest that all PKU
patients should have a trial with the cofactor, except those
with two truncating mutations in trans (Vockley et al.,
2014). The next decades will continue to show how the cul-
ture of genetics will create precision medicine for many dis-
eases, metabolic, and chromosomal.
5 | TRAINING IN MEDICAL
GENETICS AND GENOMICS
The first department of Medical Genetics in the United
States was established at Bowman Gray School of Medicine
(now called Wake Forest University Baptist Medical Cen-
ter) in 1941. Dr. William Allan was the first chairman and
served in that capacity until his death in 1943. The creation
of the department was funded by a $50,000 grant from the
Carnegie Corporation of New York (Meads & Davis,
1988). Dr. Allan also established the first human genetics
course in a medical school. Dr. Allan’s records are housed
in the Dorothy Carpenter Medical Archives in Winston-
Salem, NC (William Allan Papers, Special Collections at
Belk Library). A subset of the records on over 250 families
from western North Carolina is currently housed at Appala-
chian State University. Dr. Allan’s contributions to the field
of human genetics is recognized by the American Society
of Human Genetics (ASHG) through its Allan Award, cre-
ated in 1961 and awarded “to recognize substantial and far-
reaching scientific contributions to human genetics carried
out over a sustained period of scientific inquiry and produc-
tivity” (ASHG Awards). ASHG considers the Allan Award
to be its highest award.
There are 45 programs in the U.S. that offer Medical
Genetics and Genomics (MGG) residencies and fellowships
for individuals with an M.D. or D.O (http://www.acgme.
org/). These programs are a minimum of 2 years but often
require a third year. Combined residencies exist for Pedi-
atrics and MGG (n = 16) (List of accredited combined resi-
dency programs—MGG-Peds) and Internal Medicine and
MGG (n = 5) (List of accredited combined residency pro-
grams—MGG-IM). There are also combined residencies
and fellowship programs for Maternal Fetal Medicine and
MGG (n = 10) (List of accredited combined residency pro-
grams—MFM-MGG) and Reproductive Endocrinology and
Infertility and MGG (n = 3) (List of accredited combined
residency programs—REI-MGG). Sixteen programs offer
training in Medical Biochemical Genetics, a 1-year pro-
gram available to individuals who have completed another
residency. Molecular Genetic Pathology programs are
offered by 39 institutions (http://www.acgme.org/).
Clinicians and PhDs can participate in the laboratory-
based fellowships. Historically, training was offered in
Clinical Biochemical Genetics (n = 43), Clinical Cytoge-
netics and Genomics (n = 24), and Clinical Molecular
Genetics and Genomics (n = 42) (ABMGG Accredited
Programs—LGG). The laboratory-based fellowships require
2 years of training, unless another genetics specialty has
been completed. In that case the additional specialty can be
completed in 1 year. As of July 1, 2017, Clinical Cytoge-
netics and Genomics and Molecular Genetics and Geno-
mics have been combined into the 2-year Laboratory
Genetics and Genomics (LGG) program (n = 29). Some
LGG programs require 3 years.
Three groups oversee the training and practice of medi-
cal genetics in the United States. Accreditation of medical
genetics and genomics residency programs is through the
Accreditation Council for Graduate Medical Education
(ACMGE; http://www.acgme.org/) Residency Review
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Committee (RRC). This organization also accredits the
Medical Biochemical Genetics and Molecular Genetic
Pathology subspecialty programs. The second organization
is the American Board of Medical Genetics and Genomics
(ABMGG; www.abmgg.org), which accredits the labora-
tory fellowship programs. Individuals who received their
clinical training or PhDs outside of the United States may
be eligible to participate in the laboratory fellowships. To
determine eligibility, individuals must submit their creden-
tials to ABMGG for review. ACGME recently agreed to
assume the accreditation of the laboratory programs. This
transition is expected to take approximately 2–3 years.
ABMGG also administers the genetics and genomics certi-
fication examinations, which are offered in August of odd
years. All trainees take an examination of general genetics
and genomics knowledge as well as an examination of
knowledge specific to the specialty of training. To become
certified, the trainee must pass both exams. As of the
2015 examination, there are 1,594 clinical geneticists, 333
clinical biochemical geneticists, 770 clinical cytogeneti-
cists, 685 clinical molecular, 49 clinical biochemical and
molecular (examination only offered 1 year), and 63 medi-
cal biochemical geneticists (Number of ABMGG-certified
specialists in Medical Genetics and Genomics). Data from
the 2017 examination were not available at the time this
article was written. The third organization is the American
College of Medical Genetics and Genomics (ACMGG;
www.acmg.net). ACMGG issues policy statements and
practice guidelines for both clinical and laboratory prac-
tices, provides educational resources, and works to ensure
genetics and genomics are incorporated appropriately into
medical practice. The organization also hosts an annual
meeting in the spring.
6 | GENETIC COUNSELING
The term “genetic counseling” was coined by Sheldon Reed
in 1947 (Reed, 1974). Reed, who held a doctorate in Genet-
ics, proposed that the term genetic counseling be used in
place of terms to which he objected, for example, genetic
consultation, genetic advice (Resta, 2006). The currently
accepted definition of genetic counseling was proposed by a
committee of the National Society of Genetic Counseling
(NSGC) in 2006 and is as follows (National Society of
Genetic Counselors’ Definition Task Force et al., 2006):
“The process of helping people was to understand and
adapt to the medical, psychological and familial implica-
tions of genetic contributions to disease. This process inte-
grates the following:
1. Interpretation of family and medical histories to assess
the chance of disease occurrence or recurrence.
2. Education about inheritance, testing, management, pre-
vention, resources, and research.
3. Counseling to promote informed choices and adaptation
to the risk or condition.”
While professionals with various backgrounds and train-
ing may provide genetic information to patients and their
families, certification as a genetic counselor requires special-
ized training in medical genetics and counseling. Training
and certification as a genetic counselor within the United
States requires: (1) the successful completion of a Masters
level program accredited by the Accreditation Council for
Genetic Counseling (ACGC; http://www.gceducation.org)
and (2) passing a certifying examination overseen by the
American Board of Genetic Counseling (ABGC; http://
www.abgc.net/home//). At the time of the submission of this
manuscript, there were 37 ACGC-accredited programs
within the United States and 5 additional programs that have
submitted a letter of intent proposing new programs. Like-
wise, there are currently over 4,000 ABGC-certified genetic
counselors within the US.
Since the first genetic counseling program was initiated
at Sarah Lawrence College in 1969, the profession has
grown dramatically. The U.S. Bureau of Labor Statistics
projects a growth rate of 29% for genetic counseling posi-
tions over the years from 2014 to 2024. This far exceeds
the average growth rate of 7% for all occupations (Genetic
Counselors—Occupational Outlook Handbook, U.S.
Bureau of Labor Statistics).
The National Society of Genetic Counselors conducts
an annual survey of genetic counselors to collect data about
the profession (National Society of Genetic Counselors—
2016 Professional Status Survey Reports). In 2016, 58% of
those responding reported that they work in a “clinical”
position, 22% work in a nonclinical position, and 19%
report working in a mixed (clinical and nonclinical) posi-
tion. Of genetic counselors seeing patients, the majority
work at a university medical center (36%), public (21%), or
private (19%) hospitals with 48% providing services in can-
cer genetics clinics, 43% in prenatal diagnostic clinics, 25%
in pediatrics, 19% in general genetics, 15% adult genetics
clinics including complex diseases, and 10% in cardiology
clinics. Genetic counselors working in nonclinical positions
work primarily in commercial, nonacademic diagnostic lab-
oratories (49%), university medical centers (14%), commer-
cial academic labs (8%), public/private medical facilities
(7%), and 22% in a collection of other settings.
Other health care professionals providing genetic coun-
seling services may include clinical Geneticists (physi-
cians), and other genetics subspecialists (biochemical,
molecular, and cytogeneticists), genetics nurses, and non-
geneticists (primary or specialty care physicians who are
not geneticists). There are a significant number of nurses
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working in Genetics, such that they have their own profes-
sional society, the International Society of Nurses in Genet-
ics (ISONG). The genetics nursing credentialing
commission uses a portfolio-based mechanism for appropri-
ately prepared nurses to become credentialed in genetic
nursing (http://www.isong.org).




Given the breadth and depth of the topics presented within
this section, our intent is to provide a listing of the most
widely recognized resources providing an entry point into
exploring each topic in greater detail.
7.1 | Patient advocacy and support resources
Educational and support groups created and maintained by
patients and parents fill an enormous void in helping fami-
lies learn about, cope with, identify resources, and move
forward following a diagnosis or the journey to find one.
Thousands of patient and family support groups exist and
are readily identified through Internet searches. However,
we list a few resources that can assist families and health
care professionals quickly and safely find credible informa-
tion and resources to advocate for services on their behalf
(Table 1).
7.2 | Genetic registries
Broadly speaking, genetic registries are databases of
information collected on individuals with a specific inher-
ited or genetic disease or condition. The data collected in
registries will vary depending on the specific purpose(s)
of the registry. Some registries exist to facilitate contact
of patients with clinicians and are useful for organizing
the disease community and clinical cohorts. Other reg-
istries exists to facilitate the advancement of research and
include clinical and/or laboratory information. The
resources listed below will provide a few widely used
resources; however, they do not represent an exhaustive
list (Table 2).
7.3 | Additional resources
1. Online Mendelian Inheritance in Man (OMIM)
(https://www.omim.org/)
A comprehensive, authoritative compendium of human
genes and genetic phenotypes that is freely available
and updated daily. The full-text, referenced overviews
in OMIM contain information on all known Mendelian
disorders and over 15,000 genes. OMIM is intended
for use primarily by physicians and other professionals
concerned with genetic disorders, by genetics research-




An international point-of-care resource for busy
clinicians, that provides clinically relevant and medi-
cally actionable information for inherited conditions
in a standardized journal-style format, covering diag-
nosis, management, and genetic counseling for
patients and their families. Each chapter in GeneRe-
views is written by one or more experts on the
specific condition or disease and goes through a rig-
orous editing and peer review process before being
published online.
3. PubMed, National Library of Medicine
(http://www.ncbi.nlm.nih.gov/PubMed/)
Basic search engine for biomedical research, including
research and commentary regarding clinical research
ethics and regulations.
4. Center for Disease Control and Prevention, Public
Health Genomics
(https://www.cdc.gov/genomics/)
Provides timely and credible information for the effec-
tive and responsible translation of genomics research
into population health benefits.
5. U.S. Surgeon General’s My Family Health Portrait
(https://familyhistory.hhs.gov/FHH/)
A web-based tool to collect family health history infor-
mation to share with doctors and family members.
6. ClinicalTrials.gov
(https://clinicaltrials.gov)
A resource provided by the National Library of Medi-
cine, this is a database of privately and publicly funded
clinical studies conducted around the world.
7. National Newborn Screening and Genetics Resource
Center
(http://genes-r-us.uthscsa.edu/)
Provides information and resources in the area of new-
born screening and genetics to benefit health profession-
als, the public health community, consumers, and
government officials.
8. National Information Resource on Ethics & Human
Genetics
(http://bioethics.georgetown.edu/nirehg/)
From Georgetown University and funded by the
National Human Genome Research Institute, this
resource supports information services on topics related
to ethics and human genetics.
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8 | CONCLUDING REMARKS
We summarized the history and the current state of medical
genetics and genomics in the United States. The information
herein included is, however, subject to constant change, as
the number of certified genetic providers, commercially
available genetic tests, advocacy groups and registries, and
online resources is in permanent flux. Thus, although the
TABLE 1 Genetics Resources. The name of the resource, website, and short description of resources are shown that can be helpful for the
clinician caring for patients with genetic syndromes
Genetics organization (website) Short description
The Genetic and Rare Disease Information Center (GARD)
https://rarediseases.info.nih.gov/
GARD is a program of the National Center for Advancing Translational Sciences
(NCATS) and funded by two parts of the National Institutes of Health (NIH):
NCATS and the National Human Genome Research Institute (NHGRI). GARD
provides the public with access to current, reliable, and easy to understand
information about rare or genetic diseases. Information is available in English or
Spanish
Genetics Home Reference (GHR)
https://ghr.nlm.nih.gov/
Genetics Home Reference provides consumer-friendly information about the
effects of genetic variation on human health. GHR provides information on:
(1) over 1,200 health conditions, diseases and syndromes; (2) over 1,400 genes
and the health effects of genetic changes; (3) chromosomes and mitochondrial
DNA; and (4) an introduction to fundamental topics related to human genetics,
including illustrations and basic explanations of genetics concepts
Genes and Disease, National Center for
Biotechnology Information, National Library of Medicine
https://www.ncbi.nlm.nih.gov/books/NBK22183/
Collection of articles that discuss genes and the diseases that they cause. These
genetic disorders are organized by the parts of the body that they affect. As
some diseases affect various body systems, they appear in more than one
chapter. With each genetic disorder, the underlying mutation(s) is discussed,
along with clinical features and links to key websites
World Health Organization (WHO)
http://www.who.int/genomics/en
WHO’s Human Genomics in Global Health Initiative aims to provide information
and raise awareness within the health sector, governments and the wider public




A nonprofit health advocacy organization that transforms health through genetics,
promoting an environment of openness centered on the health of individuals,
families, and communities. The Alliance provides a search tool (Disease
InfoSearch: http://www.diseaseinfosearch.org/) that will locate quality
information from a database of more than 13,000 conditions and thousands of
support groups and foundations
The National Organization of Rare Disorders (NORD)
https://rarediseases.org
A 501(c)(3) organization, NORD is a patient advocacy organization dedicated to
individuals with rare diseases and the organizations that serve them. NORD,
along with its more than 260 patient organization members, is committed to the
identification, treatment, and cure of rare disorders through programs of
education, advocacy, research, and patient services
Maternal and Child Health Bureau
(MCHB) within the Health Resources
and Services Administration (HRSA)
https://mchb.hrsa.gov/maternal-child-
health-topics/children-and-youth-special-health-needs
MCHB provides leadership and resources to the nation in order to improve the
quality of life for children with special health needs and their families. MCHB
provides support for programs that support states, communities, and
organizations to improve systems of care for all children with special health care
needs
Coalition for Genetic Fairness
www.geneticfairness.org/
Advocacy group for federal legislation regarding genetics discrimination through
the National Partnership for Women & Families
The American Society of Human Genetics (ASHG)
www.ashg.org
Part of the mission of ASHG is “to advance human genetics in science, health
and society”. According to their mission statement, “this mission is only
possible if the right policies are in place to support scientific discovery, the
translation of scientific discoveries into health advances, and the appropriate
application of genetics in society”. ASHG therefore analyzes emerging policy
issues, comments on pending legislation and regulations, and advocates for
evidence-based policies that benefit science, personal and public health, and
society at large
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historical aspects of this two-part review will remain unal-
tered, the rest of it will benefit from frequent updates. The
reader can refer to the pertinent references, some of which
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